Bioventus has announced that it has entered into a definitive agreement to acquire Misonix—a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine.
The acquisition is expected to boost Misonix’s BoneScalpel and Nexus adoption through Bioventus’ spine surgical solutions footprint.
Under the terms of the agreement, Misonix stockholders will receive aggregate consideration that values Misonix at approximately $518 million. The transaction is subject to regulatory approvals, Bioventus stockholder approval, Misonix stockholder approval, and other customary closing conditions. It is expected to close in the fourth quarter of 2021.
Ken Reali, chief executive officer of Bioventus, said: “We are excited to further establish Bioventus as a differentiated, growth-focused medical technology company with deep and broad capabilities across a range of care settings and specialties.
“We believe this acquisition will accelerate our growth opportunities, enhance our double-digit revenue growth, and provide a significant opportunity for long-term margin expansion. We believe the combination with Misonix will create significant value for our shareholders and enable us to better serve our customers with more comprehensive solutions and a broader portfolio.”
Stavros Vizirgianakis, chief executive officer of Misonix, added: “We are thrilled to announce this agreement to combine with Bioventus and realise our next phase of commercial development.
“Bioventus shares Misonix’s commitment to improving patient outcomes, and we believe this combination will create value for our shareholders as the combined organisation continues to drive innovation and increase physician demand.”